Overview:
The Epilepsy Market Size is
expected to reach USD 1.10 Billion by 2032 at 7.2% CAGR during the forecast
period 2023-2032.
The
epilepsy market, encompassing a wide array of pharmaceuticals, medical devices,
and therapies for managing this neurological disorder characterized by
recurrent seizures, has experienced significant growth and innovation recently.
Antiepileptic drugs (AEDs) are pivotal in epilepsy management, with ongoing
expansion fueled by the development of novel compounds offering enhanced
efficacy and fewer side effects, alongside increased accessibility and
affordability through generic versions of branded AEDs. Medical devices like
vagus nerve stimulators (VNS), responsive neurostimulation (RNS) systems, and
deep brain stimulators (DBS) have also revolutionized treatment options,
particularly for drug-resistant epilepsy patients, opening up new avenues for
seizure control and management. Additionally, research into personalized
medicine and precision therapies shows promise for tailored interventions based
on individual patient profiles and genetic markers, aiming to optimize
treatment outcomes and enhance patient quality of life. Overall, the epilepsy
market is continually evolving with advancements in pharmaceuticals, medical
devices, and personalized therapies, offering hope for improved seizure
management and better patient outcomes worldwide.
The
Epilepsy market is undergoing significant advancements to address the
multifaceted challenges associated with epilepsy and seizures. With an
estimated 65 million people worldwide living with epilepsy, the demand for
innovative treatments and management strategies remains paramount.
Pharmaceutical companies are actively engaged in research and development
efforts aimed at bringing novel therapies to market to address the unmet
medical needs of individuals affected by epilepsy disease. These efforts
encompass a wide range of approaches, including the development of
antiepileptic drugs (AEDs) with improved efficacy and safety profiles, as well
as the exploration of non-pharmacological interventions such as medical devices
and surgical procedures. Additionally, there is a growing focus on personalized
medicine approaches tailored to individual patient profiles, aiming to optimize
treatment outcomes and minimize adverse effects.
Competitive Landscape:
MRFR’s
analysis of various companies to get close to factors that can decipher the
market growth and assist in the implementation of several market strategies.
The recording of these moves can inspire a better understanding of the global
scenario. Epilepsy Market Players are.
GlaxoSmithKline
PLC (U.K.),
LivaNova
PLC (U.K.),
Medtronic
PLC (Ireland),
Eisai
Co. Ltd. (Japan),
Pfizer
Inc. (U.S.),
NeuroPace
Inc. (U.S.),
UCB
SA (Belgium),
Johnson
& Johnson Services Inc. (U.S.),
Novartis
AG (Switzerland),
GW
Pharmaceuticals PLC (U.K.),
Abbott
Laboratories (U.S.).
These Epilepsy companies are
set on a path to solidify their own market stance and improve scopes for
expansion in the coming days.
Segmentation:
The
report on the epilepsy market encompasses segments like by condition,
diagnosis & treatment, and end-use to facilitate an easy understanding of
the market and gauge well how the regional market would shape up in the coming
years.
- By
condition, the market report on epilepsy
covers epilepsy
drug-resistant/intractable epilepsy and others. The former
had a market share of 29.5% in 2017. The global market for the segment can
provide ample growth opportunities as the requirement for drug-resistant
therapies can trigger better growth. The ‘others’ segment has a market
growth possibility of 7.83% CAGR during the forecast period.
- By
diagnosis and treatment, the market report on epilepsy
includes diagnosis and treatment. The diagnosis segment can be
sub-segmented into blood tests, imaging devices, and others. The treatment
segment includes neurostimulation devices, anti-epileptic drugs,
ketogenic diet, brain surgery, and others. The treatment segment had 66.2%
of the global share in 2017. Cost-efficiency can be taken into
consideration to understand market growth possibilities.
- By
end-users, the epilepsy market can include
clinics, hospitals, diagnostic centers, ambulatory surgical centers, and
others. The hospital segment had a market share of 29.3% in 2017.
Regional Analysis:
The
global market, upon considering from a region-specific angle, can be segmented
into North America, Europe, and the Asia Pacific as major contributors. It also
covers Latin America and the Middle East & Africa (MEA) as countries
displaying moderate growth but with the potential to improve scenario. The
Americas has better market coverage and it had almost 41% of the global market
share in 2017. Europe is on a track to display 8.31% CAGR during the forecast
period. The regional market has potential to explore opportunities regarding
research and development, and it is getting backed by the constant influx of
investments. Countries like the UK, France, Germany, and others are
contributing much to take the regional market ahead in the coming years.
The
Asia Pacific (APAC) market is showing opportunities to score well past a
valuation mark of USD 2,046.57 million by 2023. Most of the traction to grow
forward would come from India, South Korea, and China where a large population
is triggering high ingress of treatments needed for that.
Related reports-
Saliva Collection and
Diagnostics
For more information, Please Visit us @ Market Research Future
